Find out more about the headlines from the Conference on Retroviruses and Opportunistic Infections 2019 (CROI) in our round-up of conference news.
Researchers have investigated a toxin–antitoxin system in tuberculosis as a therapeutic target, providing the first high-resolution details.
Meeting report: Non-tuberculous mycobacterial lung disease at the 2018 International Congress of the European Respiratory Society
The International Congress of the European Respiratory Society, 15–19 September, Paris (France), is the largest respiratory medicine meeting in the world. Find out about the latest research on non-tuberculous mycobacteria lung disease (NTM-LD) discussed at the 2018 congress in this report.
New data analysis of three clinical trials has suggested that a precision medicine approach could allow some pulmonary TB patients to have significantly shorter treatment periods.
On the day of UNGA’s first-ever high-level meeting on tuberculosis we summarize the key points from the WHO 2018 Global Tuberculosis Report and what this meeting could mean for accelerating progress.
A study using standardized patients has reported that private practitioners in India are delivering a wide range of often inadequate care to tuberculosis patients.
Scientists at the University of Manchester (UK) have developed the first non-antibiotic drug to successfully…
Clinical trial data has proved a novel, short therapy more effective and safe for the treatment of latent tuberculosis than the standard therapy in both adults and children.
Guy Thwaites, Director of the Oxford University Clinical Research Unit/Wellcome Program in Vietnam, speaks on neurotuberculosis and the challenges it faces in terms of treatment, HIV co-infection and the political will necessary for change.
A peek behind the paper – better than a pound of cure; steps to prevent multidrug resistant tuberculosis in adults and children
Take a look behind the science of a recent Future Microbiology article, entitled ‘Better than a pound of cure: preventing the development of multidrug-resistant tuberculosis’ as we ask the authors about the challenges currently facing multidrug resistant (MDR) tuberculosis and what the future might hold.